Go Deep
Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,259 | 11.7 | 3.05 | 0.13 | 255.73 |
| Oct 2026 | 20,430 | 11.4 | 2.96 | 0.13 | 248.15 |
| Oct 2026 | 20,558 | 11.1 | 2.89 | 0.13 | 242.73 |
| Oct 2026 | 20,387 | 11.5 | 2.98 | 0.13 | 250.32 |
| Oct 2026 | 20,537 | 11.2 | 2.90 | 0.13 | 243.08 |
| Oct 2026 | 20,537 | 11.2 | 2.90 | 0.13 | 242.58 |
| Oct 2026 | 20,580 | 11.1 | 2.88 | 0.13 | 241.69 |
Protalix BioTherapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 19,896,000.0 | 33,750,000.0 | 9,122,000.0 | 17,851,000.0 |
| Net Profit | 3,777,000.0 | 18,317,000.0 | -5,504,000.0 | 2,355,000.0 |
| EPS | 0.1 | 0.2 | — | 0.0 |
Protalix BioTherapeutics, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 52,744,000.0 | 53,399,000.0 | 65,494,000.0 | 47,638,000.0 |
| Net Profit | -6,604,000.0 | 2,932,000.0 | 8,312,000.0 | -14,927,000.0 |
| EPS | -0.1 | 0.0 | 0.1 | -0.3 |
Protalix BioTherapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 82,346,000.0 | 73,417,000.0 | 84,434,000.0 | 55,787,000.0 | — |
| Total Liabilities | 34,116,000.0 | 30,206,000.0 | 50,865,000.0 | 66,427,000.0 | — |
| Total Equity | 48,230,000.0 | 43,211,000.0 | 33,569,000.0 | -10,640,000.0 | — |
Owes vs Owns
Protalix BioTherapeutics, Inc. owed $0.35 for every $1 it owned in Jun 2026, down from $1.19 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.35× | 0.41× | 0.41× | 0.60× | 1.19× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Protalix BioTherapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 36.8%Receivables 10.7%Inventory 31.2%Fixed assets (tangible) 15.3%Other assets 6.0%
How it's funded — Dec 2025
Short-term debt 1.7%Long-term debt 8.4%Payables 6.4%Other liabilities 24.9%Shareholders' equity 58.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 30.3 | 34.8 | 44.6 | 22.2 |
| Receivables | 8.8 | 2.9 | 5.3 | 4.6 |
| Inventory | 25.7 | 21.2 | 19.0 | 16.8 |
| Fixed assets (tangible) | 12.6 | 10.0 | 10.9 | 9.6 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 4.9 | 4.4 | 4.7 | 2.6 |
| Liabilities & equity | ||||
| Short-term debt | 1.4 | 1.5 | 20.3 | 1.1 |
| Long-term debt | 6.9 | 4.0 | 4.6 | 28.2 |
| Payables | 5.3 | 4.5 | 4.3 | 5.9 |
| Other liabilities | 20.5 | 20.1 | 21.7 | 31.3 |
| Shareholders' equity | 48.2 | 43.2 | 33.6 | -10.6 |
| Net tangible assets | 48.2 | 43.2 | 33.6 | -10.6 |
Protalix BioTherapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -11,993,000.0 | 8,674,000.0 | -1,318,000.0 | -25,000,000.0 | — |
| Investing Activities | -2,366,000.0 | 4,221,000.0 | -16,711,000.0 | -5,035,000.0 | — |
| Financing Activities | 9,326,000.0 | -16,794,000.0 | 24,666,000.0 | 8,238,000.0 | — |